MicroRNAs: Role in hepatitis C virus pathogenesis

Genes and Diseases

Volumn 2, Issue 1, 2015, Pages 35-45

  Shrivastava, Shubham ^a   Steele, Robert ^a   Ray, Ranjit ^a   Ray, Ratna B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Circulatory miRNAs; HCV; Interferon signaling; Liver disease; MicroRNA

Indexed keywords

ALPHA INTERFERON; ARGONAUTE PROTEIN; BETA INTERFERON; CLAUDIN 1; CYCLOPHILIN A; DICER; FAT DROPLET; MICRORNA; MICRORNA 122; MICRORNA 143; MICRORNA 145; MICRORNA 221; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; OCCLUDIN; PEGINTERFERON; PHOSPHATIDYLINOSITOL KINASE; RIBAVIRIN; SCAVENGER RECEPTOR BI; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS PROTEIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; APOPTOSIS; BIOGENESIS; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; END STAGE LIVER DISEASE; ENDOPLASMIC RETICULUM; FATTY LIVER; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LIFE CYCLE; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; RISK FACTOR; RNA DEGRADATION; SECRETORY PATHWAY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIREMIA; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84978160668     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2015.01.001     Document Type: Review

References (103)

1. Moradpour D., Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 2013, 369:113-142.
2. Shulla A., Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol 2012, 2:725-732.
3. Gravitz L. Introduction: a smouldering public-health crisis. Nature 2011, 474:S2-S4.
4. Smith B.D., Morgan R.L., Beckett G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012, 61(RR-4):1-32. Centers for Disease Control and Prevention.
5. Kanwal F., Hoang T., Kramer J.R., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140:1182 e1-1188 e1.
6. Thomas D.L. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013, 19:850-858.
7. Pawlotsky J.M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014, 146:1176-1192.
8. deLemos A.S., Chung R.T. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014, 20:315-321.
9. Schinazi R., Halfon P., Marcellin P., Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014, 34(suppl 1):69-78.
10. Rupp D., Bartenschlager R. Targets for antiviral therapy of hepatitis C. Semin Liver Dis 2014, 34:9-21.
11. Zeisel M.B., Lupberger J., Fofana I., Baumert T.F. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol 2013, 58:375-384.
12. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
13. Henke J.I., Goergen D., Zheng J., et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008, 27:3300-3310.
14. Roberts A.P., Lewis A.P., Jopling C.L. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 2011, 39:7716-7729.
15. Jangra R.K., Yi M., Lemon S.M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010, 84:6615-6625.
16. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
17. Janssen H.L., Reesink H.W., Lawitz E.J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
18. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
19. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
20. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11:597-610.
21. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014, 15:509-524.
22. Hausser J., Zavolan M. Identification and consequences of miRNA-target interactions-beyond repression of gene expression. Nat Rev Genet 2014, 15:599-612.
23. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11:228-234.
24. Ørom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 30:460-471.
25. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 2008, 105:1608-1613.
26. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
27. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
28. Swaminathan G., Martin-Garcia J., Navas-Martin S. RNA viruses and microRNAs: challenging discoveries for the 21st century. Physiol Genomics 2013, 45:1035-1048.
29. Roberts A.P., Lewis A.P., Jopling C.L. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 2011, 102:101-139.
30. Shrivastava S., Mukherjee A., Ray R.B. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013, 5:479-486.
31. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011, 108:3193-3198.
32. Li Y., Masaki T., Yamane D., McGivern D.R., Lemon S.M. Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 2013, 110:1881-1886.
33. Nasheri N., Singaravelu R., Goodmurphy M., Lyn R.K., Pezacki J.P. Competing roles of microRNA-122 recognition elements in hepatitis C virus RNA. Virology 2011, 410:336-344.
34. Narbus C.M., Israelow B., Sourisseau M., et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011, 85:12087-12092.
35. Kambara H., Fukuhara T., Shiokawa M., et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 2012, 86:1382-1393.
36. Fukuhara T., Kambara H., Shiokawa M., et al. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol 2012, 86:7918-7933.
37. Pedersen I.M., Cheng G., Wieland S., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
38. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a*. J Hepatol 2009, 50:453-460.
39. Cheng J.C., Yeh Y.J., Tseng C.P., et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012, 69:2621-2633.
40. Mukherjee A., Shrivastava S., Bhanja Chowdhury J., Ray R., Ray R.B. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol 2014, 88:7929-7940.
41. Shrivastava S., Ray R.B. Hepatitis C virus infection, autophagy and innate immune response. Autophagy. Cancer, Other Pathologies, Inflammation, Immunity, Infection and Aging 2014, vol. 3:164-190. Academic Press, Elsevier.
42. Bhanja Chowdhury J., Shrivastava S., Steele R., Di Bisceglie A.M., Ray R., Ray R.B. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2012, 86:10221-10225.
43. Raychoudhuri A., Shrivastava S., Steele R., Kim H., Ray R., Ray R.B. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011, 85:12881-12889.
44. Wilkins C., Woodward J., Lau D.T., et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013, 57:461-469.
45. Zhang X., Daucher M., Armistead D., Russell R., Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-α. PLoS One 2013, 8:e55733.
46. Li S., Duan X., Li Y., Liu B., McGilvray I., Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat 2014, 21:121-128.
47. Chen Y., Chen J., Wang H., et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013, 9:e1003248.
48. Yang Q., Fu S., Wang J. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. Arch Virol 2014, 159:2997-3003.
49. Yoshikawa T., Takata A., Otsuka M., et al. Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep 2012, 2:637.
50. Xu G., Yang F., Ding C.L., et al. MiR-221 accentuates IFN[U+05F3]s anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014, 462-463:343-350.
51. Bruni R., Marcantonio C., Tritarelli E., et al. An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones. BMC Genomics 2011, 12:485.
52. Cheng M., Si Y., Niu Y., et al. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol 2013, 87:9707-9718.
53. Murakami Y., Tanaka M., Toyoda H., et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 2010, 3:48.
54. Sarasin-Filipowicz M., Krol J., Markiewicz I., Heim M.H., Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009, 15:31-33.
55. Estrabaud E., Lapalus M., Broët P., et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol 2014, 88:6394-6402.
56. Köberle V., Waidmann O., Kronenberger B., et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Viral Hepat 2013, 20:530-535.
57. Shirasaki T., Honda M., Shimakami T., et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013, 87:5270-5286.
58. Elhelw D.S., Mekky R.Y., El-Ekiaby N., et al. Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep 2014, 2:843-848.
59. McFarland A.P., Horner S.M., Jarret A., et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014, 15:72-79.
60. Jiang M., Broering R., Trippler M., et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat 2014, 21:99-110.
61. Bala S., Tilahun Y., Taha O., et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 2012, 10:151.
62. Hsi E., Huang C.F., Dai C.Y., et al. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Res 2014, 105:135-142.
63. Choi Y., Dienes H.P., Krawczynski K. Kinetics of miR-122 expression in the liver during acute HCV infection. PLoS One 2013, 8:e76501.
64. Fehr C., Conrad K.D., Niepmann M. Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases. Cell Cycle 2012, 11:277-285.
65. Hou W., Bukong T.N., Kodys K., Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013, 37:599-608.
66. Bukong T.N., Hou W., Kodys K., Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013, 57:70-80.
67. Sendi H., Mehrab-Mohseni M., Foureau D.M., et al. miR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA. Liver Int 2014, [Epub ahead of print]. 10.1111/liv.12698.
68. Hou W., Tian Q., Zheng J., Bonkovsky H.L. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010, 51:1494-1504.
69. Jabłonowska E., Wójcik K., Szymańska B., Omulecka A., Cwiklińska H., Piekarska A. Hepatic HMOX1 expression positively correlates with Bach-1 and miR-122 in patients with HCV mono and HIV/HCV coinfection. PLoS One 2014, 9:e95564.
70. Peng X., Li Y., Walters K.A., et al. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 2009, 10:373.
71. Steuerwald N.M., Parsons J.C., Bennett K., Bates T.C., Bonkovsky H.L. Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. Liver Int 2010, 30:1490-1504.
72. Liu X., Wang T., Wakita T., Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 2010, 398:57-67.
73. Schuppan D., Krebs A., Bauer M., Hahn E.G. Hepatitis C and liver fibrosis. Cell Death Differ 2003, 10(suppl 1):S59-S67.
74. Marquez R.T., Bandyopadhyay S., Wendlandt E.B., et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010, 90:1727-1736.
75. Bandyopadhyay S., Friedman R.C., Marquez R.T., et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis 2011, 203:1753-1762.
76. Ramachandran S., Ilias Basha H., Sarma N.J., et al. Hepatitis C virus induced miR200c down modulates FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. PLoS One 2013, 8:e70744.
77. Sarma N.J., Tiriveedhi V., Subramanian V., et al. Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One 2012, 7:e50826.
78. Sarma N.J., Tiriveedhi V., Crippin J.S., Chapman W.C., Mohanakumar T. Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. JVirol 2014, 88:3733-3743.
79. Goossens N., Negro F. Is genotype 3 of the hepatitis C virus the new villain?. Hepatology 2014, 59:2403-2412.
80. Singaravelu R., Chen R., Lyn R.K., et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology 2014, 59:98-108.
81. Boštjančič E., Bandelj E., Luzar B., Poljak M., Glavač D. Hepatic expression of miR-122, miR-126, miR-136 and miR-181a and their correlation to histopathological and clinical characteristics of patients with hepatitis C. J Viral Hepat 2014, [Epub ahead of print]. 10.1111/jvh.12266.
82. Raimondi S., Bruno S., Mondelli M.U., Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009, 50:1142-1154.
83. Law P.T., Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. JGastroenterol Hepatol 2011, 26:437-449.
84. Huang S., He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011, 104:235-240.
85. Giordano S., Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?. Hepatology 2013, 57:840-847.
86. Zhang Y., Wei W., Cheng N., et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.
87. Banaudha K., Kaliszewski M., Korolnek T., et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011, 53:53-61.
88. Huang S., Xie Y., Yang P., Chen P., Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One 2014, 9:e81730.
89. Ishida H., Tatsumi T., Hosui A., et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011, 412:92-97.
90. Varnholt H., Drebber U., Schulze F., et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
91. Ura S., Honda M., Yamashita T., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
92. Lemoinne S., Thabut D., Housset C., et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol 2014, 11:350-361.
93. Schwarzenbach H., Nishida N., Calin G.A., Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014, 11:145-156.
94. Shrivastava S., Petrone J., Steele R., Lauer G.M., Bisceglie A.M., Ray R.B. Upregulation of circulating miR-20a is correlated with hepatitis C virus mediated liver disease progression. Hepatology 2013, 58:863-871.
95. Shwetha S., Gouthamchandra K., Chandra M., Ravishankar B., Khaja M.N., Das S. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 2013, 3:1555.
96. Bihrer V., Friedrich-Rust M., Kronenberger B., et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011, 106:1663-1669.
97. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
98. Starkey Lewis P.J., Dear J., Platt V., et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54:1767-1776.
99. Bala S., Petrasek J., Mundkur S., et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56:1946-1957.
100. van der Meer A.J., Farid W.R., Sonneveld M.J., et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. JViral Hepat 2013, 20:158-166.
101. Bihrer V., Waidmann O., Friedrich-Rust M., et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011, 6:e26971.
102. Trebicka J., Anadol E., Elfimova N., et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013, 58:234-239.
103. Abdalla M.A., Haj-Ahmad Y. Promising candidate urinary microrna biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients. J Cancer 2012, 3:19-31.